Jane Street Group, LLC Biocryst Pharmaceuticals Inc Call Options Transaction History

Jane Street Group, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $568,567 - $770,803	88,700 New	88,700 $674,000
Q1 2022 May 17, 2022	BUY	$11.56 - $19.76 $2.72 Million - $4.65 Million	235,100 Added 45.33%	753,700 $12.3 Million
Q4 2021 Feb 15, 2022	SELL	$11.18 - $15.46 $1.48 Million - $2.05 Million	-132,600 Reduced 20.36%	518,600 $7.18 Million
Q3 2021 Nov 16, 2021	BUY	$14.21 - $17.65 $1.05 Million - $1.3 Million	73,600 Added 12.74%	651,200 $9.36 Million
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $618,450 - $1.12 Million	-65,100 Reduced 10.13%	577,600 $9.13 Million
Q1 2021 May 18, 2021	BUY	$7.37 - $13.61 $2.14 Million - $3.96 Million	291,000 Added 82.74%	642,700 $6.54 Million
Q4 2020 Feb 17, 2021	BUY	$3.37 - $8.61 $711,744 - $1.82 Million	211,200 Added 150.32%	351,700 $2.62 Million
Q3 2020 Nov 17, 2020	SELL	$3.43 - $5.53 $419,832 - $676,872	-122,400 Reduced 46.56%	140,500 $483,000
Q2 2020 Aug 17, 2020	BUY	$1.9 - $5.61 $499,510 - $1.47 Million	262,900 New	262,900 $1.25 Million

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.